New hope for fighting back against aggressive brain tumors
NCT ID NCT02942264
Summary
This study tested if adding an experimental drug called Zotiraciclib to a standard chemotherapy (temozolomide) could better control aggressive brain tumors that have returned after initial treatment. The trial had two parts: first to find a safe dose, then to compare how long the combination kept the tumor from growing versus the standard drug alone. It was for adults whose anaplastic astrocytoma or glioblastoma had come back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.